Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
暂无分享,去创建一个
F. Gonzalez | G. Elizondo | A. Yu | K. Krausz | T. Akiyama | L. Feigenbaum | C. Cheung | C. Granvil
[1] D. Russell,et al. Clinical importance of the cytochromes P450 , 2002, The Lancet.
[2] B. Ring,et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[3] P. Anzenbacher,et al. Cytochromes P450 and experimental models of drug metabolism , 2002, Journal of Cellular and Molecular Medicine.
[4] T. Willson,et al. Pxr, car and drug metabolism , 2002, Nature Reviews Drug Discovery.
[5] W. Charman,et al. The Mucosa of the Small Intestine , 2002, Clinical pharmacokinetics.
[6] P. Watkins,et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. , 2001, Pharmacogenetics.
[7] Karthik Venkatakrishnan,et al. Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models , 2001, Journal of clinical pharmacology.
[8] L. Wienkers,et al. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. , 2001, Archives of biochemistry and biophysics.
[9] A. Nafziger,et al. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. , 2001, Pharmacogenetics.
[10] L. Wienkers. Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery. , 2001, Journal of pharmacological and toxicological methods.
[11] J. Idle,et al. The CYP 2 D 6 Humanized Mouse : Effect of the Human CYP 2 D 6 Transgene and HNF 4 on the Disposition of Debrisoquine in the Mouse , 2001 .
[12] J. Schellens,et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[13] F. Guengerich. Metabolism of chemical carcinogens. , 2000, Carcinogenesis.
[14] D. Greenblatt,et al. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. , 2000, The Journal of pharmacology and experimental therapeutics.
[15] H. Yamazaki,et al. Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[16] P. Watkins,et al. THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.
[17] G. Elizondo,et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity , 2000, Clinical pharmacology and therapeutics.
[18] U. Fuhr,et al. Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. , 2000, International journal of clinical pharmacology and therapeutics.
[19] G. Kearns,et al. Cytochrome P450 3A , 1999, Clinical pharmacokinetics.
[20] F. Gonzalez,et al. Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. , 1999, Trends in pharmacological sciences.
[21] F. Gonzalez,et al. Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis. , 1999, Cancer letters.
[22] F. Gonzalez,et al. Targeted Disruption of the Microsomal Epoxide Hydrolase Gene , 1999, The Journal of Biological Chemistry.
[23] D. Dunbar,et al. Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[24] M. Danhof,et al. Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats , 1999, British journal of pharmacology.
[25] F. Guengerich,et al. Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.
[26] H. Kotaki,et al. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[27] T. Murakami,et al. Dose‐dependent Intestinal and Hepatic First‐pass Metabolism of Midazolam, a Cytochrome P450 3A Substrate with Differently Modulated Enzyme Activity in Rats , 1999, The Journal of pharmacy and pharmacology.
[28] R. Scott,et al. Prognostic implications of cancer susceptibility genes: any news? , 1999, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[29] F. Gonzalez. The study of xenobiotic-metabolizing enzymes and their role in toxicity in vivo using targeted gene disruption. , 1998, Toxicology letters.
[30] D. Bailey,et al. Grapefruit juice-drug interactions. , 1998, British journal of clinical pharmacology.
[31] D. Greenblatt,et al. Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. , 1998, The Journal of pharmacology and experimental therapeutics.
[32] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[33] K. Pang,et al. First-pass effect: significance of the intestine for absorption and metabolism. , 1997, Drug and chemical toxicology.
[34] M. Katsuki,et al. In vivo activation of aflatoxin B1 in C57BL/6N mice carrying a human fetus-specific CYP3A7 gene. , 1997, Cancer research.
[35] M. Katsuki,et al. Establishment of transgenic mice carrying human fetus-specific CYP3A7. , 1996, Archives of biochemistry and biophysics.
[36] K. Korzekwa,et al. Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. , 1995, Biochemical pharmacology.
[37] P. Watkins. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation , 1995 .
[38] J. Kolars,et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[39] W. Trager,et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.
[40] J. Kolars,et al. CYP3A gene expression in human gut epithelium. , 1994, Pharmacogenetics.
[41] P. Neuvonen,et al. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole , 1994 .
[42] D. Bailey,et al. Grapefruit Juice and Drugs , 1994, Clinical pharmacokinetics.
[43] F. Gonzalez,et al. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. , 1994, Drug metabolism reviews.
[44] S. Tagawa,et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. , 1993, European journal of biochemistry.
[45] J. Kolars,et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.
[46] T. Kronbach,et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.
[47] O. Mcbride,et al. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.
[48] J W Dundee,et al. Midazolam. A review of its pharmacological properties and therapeutic use. , 1984, Drugs.